Molindone
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Molindone (Moban) is a therapeutic antipsychotic, used in the treatment of schizophrenia.[1] It works by blocking the effects of dopamine in the brain, leading to diminished psychoses. It is rapidly absorbed when taken orally.
It is sometimes described as a typical antipsychotic,[2] and sometimes described as an atypical antipsychotic.[3]
Molindone was discontinued by its sole supplier, Endo Pharmaceuticals, on January 13, 2010. [4]
Adverse effects
Adverse effects
The side effect profile of molindone is similar to that of other typical antipsychotics. Unlike most antipsychotics, however, molindone use is associated with weight loss.[3][5]
References
References
- ↑ “molindone”. F.A. Davis Company.
- ↑ Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). “Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients”. Am J Geriatr Pharmacother. 6 (4): 198–204. doi:10.1016/j.amjopharm.2008.10.003. PMID 19028375.
- ↑ 3.0 3.1 Bagnall A, Fenton M, Kleijnen J, Lewis R (2007). Bagnall, Anne-Marie, ed. “Molindone for schizophrenia and severe mental illness”. Cochrane Database Syst Rev (1): CD002083. doi:10.1002/14651858.CD002083.pub2. PMID 17253473.
- ↑ http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm
- ↑ Allison DB; Mentore JL; Heo M; et al. (1999). “Antipsychotic-induced weight gain: a comprehensive research synthesis”. Am J Psychiatry. 156 (11): 1686–96. PMID 10553730. Unknown parameter
|author-separator=ignored (help) Free full text
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH